公司及董事会全体成员保证公告内容与 Genie Pharma 提供的信息一致。 证券代码：688373 证券简称：盟科药业 公告编号：2025-051 上海盟科药业股份有限公司 关于股东 Genie Pharma 公开征集投票权的公告 股东 Genie Pharma 保证向公司提供的信息内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 重要内容提示： 按照《中华人民共和国证券法》《上市公司股东会规则》《公开征集上市公 司股东权利管理暂行规定》《上海盟科药业股份有限公司章程》或其他有关规定， 持有上市公司1%以上有表决权股份的股东Genie Pharma作为征集人，就公司拟于 1 征集投票权的起止时间：2025年9月25日至2025年10月6日 Genie Pharma（以下简称"征集人"）对上海盟科药业股份有限公司（以下简 称"公司"或"上市公司"）2025年第二次临时股东大会所审议议案除议案9 外均投反对票； 截至征集公告披露日，征集人Genie Pharma合计持有公司股份数量71,572,817 股，均为有表决权股份，占公司股份总数的10.92%； 征集人 ...

盟科药业(688373.SH)公告称，股东GeniePharma对公司2025年第二次临时股东大会所审议多项议案均投 反对票。GeniePharma合计持有公司股份数量71,572,817股，占公司股份总数的10.92%。征集投票权的 起止时间为2025年9月25日至2025年10月6日。征集人反对原因包括海鲸药业参与定增资金存在不确定 性、销售渠道和人员混同风险、募投项目进度不及预期、利用海鲸药业产能提升盈利能力不确定性以及 研发领域协同效应小等。 ...

Core Viewpoint - The company Mengke Pharmaceutical plans to issue shares to Haiqing Pharmaceutical, which will result in a change of control, with Haiqing holding 20% of the shares and becoming the controlling shareholder [6] Group 1: Share Issuance Details - Mengke Pharmaceutical intends to issue up to 163,901,373 shares at a price of 6.30 yuan per share, raising a total of no more than 1.033 billion yuan, which will be used for daily R&D and operational investments [2][4] - The issuance is aimed at enhancing the company's commercialization capabilities and expanding product sales, as the company currently has limited sales coverage and only one product on the market [4][8] Group 2: Financial Performance - Mengke Pharmaceutical's revenue for 2022, 2023, and 2024 is projected to be 482.07 million yuan, 907.76 million yuan, and 1.30 billion yuan, respectively, with a net profit of -220 million yuan, -421 million yuan, and -441 million yuan [8] - The company has maintained high R&D expenditures, with amounts of 150 million yuan, 345 million yuan, and 369 million yuan for the same years, representing 321%, 379%, and 284% of revenue [8] Group 3: Opposition to the Share Issuance - A board member opposed the share issuance, questioning the fairness, reasonableness, and synergy of the transaction, as well as the clarity of the fundraising plan [5][7] - The board member highlighted the existence of other potential investors with strong collaboration intentions, suggesting that the company did not conduct sufficient investigation and negotiation [7] Group 4: Haiqing Pharmaceutical Overview - Haiqing Pharmaceutical is a research-driven modern pharmaceutical enterprise, focusing on chemical preparations and active pharmaceutical ingredients, with significant market share in the vitamin D2 prescription drug sector [2] - The company has provided over 200 pharmaceutical research or clinical trial services to more than 100 enterprises, including major domestic pharmaceutical companies [2]

Core Viewpoint - The strategic investment by Haiqing Pharmaceutical in Mengke Pharmaceutical marks a significant shift in the latter's ownership structure, with Haiqing becoming the controlling shareholder and aiming to enhance Mengke's capabilities in the antibiotic drug development sector [1][3][4]. Financing and Ownership Changes - Mengke Pharmaceutical plans to raise 1.033 billion yuan through a private placement of 164 million shares at a price of 6.3 yuan per share, which will be used for daily research and operational expenses [3][4]. - Following the issuance, Haiqing Pharmaceutical will hold a 20% stake in Mengke and will nominate five directors to the board, giving it majority control [1][3]. - This marks the first private placement since Mengke's IPO in August 2022, which raised 1.061 billion yuan [3][4]. Financial Performance - From 2021 to mid-2025, Mengke Pharmaceutical generated total revenue of 344 million yuan but incurred a net loss of 1.447 billion yuan, with total R&D expenses amounting to 1.132 billion yuan [6][7]. - The company has not yet achieved profitability, with significant losses reported each year since its product commercialization began in 2021 [6][7]. Strategic Collaboration - A strategic cooperation agreement has been signed between Mengke and Haiqing, focusing on leveraging Mengke's expertise in multi-drug resistant bacteria and Haiqing's established R&D and commercialization capabilities [4][7]. - The collaboration aims to enhance both companies' core competitiveness and facilitate the commercialization of Mengke's products, particularly in the antibiotic sector [4][7]. Market Reaction - Following the announcement of the private placement and strategic partnership, Mengke Pharmaceutical's stock price surged by 20.02%, closing at 9.71 yuan per share [5]. Future Projections - If the collaboration is successful, Mengke aims to achieve sales revenue targets of 260 million yuan, 388 million yuan, and 600 million yuan for the years 2026, 2027, and 2028, respectively [7].

Core Viewpoint - The company plans to raise up to 1.033 billion yuan through a private placement, which will enhance its financial strength and accelerate clinical research and development efforts [4][6]. Group 1: Company Financing and Ownership Changes - The company intends to issue 164 million shares at a price of 6.3 yuan per share to Nanjing Haiqing Pharmaceutical, raising no more than 1.033 billion yuan, which will be used for daily R&D and operational investments [4]. - Following the issuance, Haiqing Pharmaceutical will hold a 20% stake in the company, becoming the controlling shareholder, with Zhang Xiantao as the actual controller [4]. Group 2: Strategic Partnerships and Market Expansion - Haiqing Pharmaceutical, a key player in the chemical pharmaceutical sector, will leverage its extensive sales network and experience to help the company expand its hospital coverage and accelerate commercialization [5]. - The company has set sales revenue targets of 260 million yuan, 388 million yuan, and 600 million yuan for the years 2026 to 2028, respectively [5]. Group 3: Clinical Development Acceleration - The financing will significantly enhance the company's capital strength, expediting the overseas clinical development of antibacterial drugs MRX-5 and MRX-8, which have already completed Phase I trials [6]. - MRX-5 has received FDA orphan drug designation, and successful Phase II trials could substantially increase the company's value [6]. - Surplus funds will also support the advancement of the company's preclinical pipeline, which includes peptide conjugates, antibody-drug conjugates, and other anti-infective drugs [6].

Group 1: Market Overview - The domestic new fund market has seen increased activity, with 63 new funds established this week. Various industry-themed funds exhibited mixed performance, with TMT-themed funds continuing to show a net value increase advantage, while financial and real estate-themed funds experienced notable pullbacks [4]. - Domestic stock ETFs have shifted to net inflows, while Hong Kong stock ETFs continue to see significant inflows. In terms of specific themes, passive funds have reduced holdings in the Sci-Tech Innovation Board and other broad-based ETFs, while financial and real estate-themed ETFs have seen significant net inflows [4]. Group 2: Company Performance - Zhongtie Assembly (300374.SZ) reported a further reduction in losses, with improved cash flow and cash collection ratios year-on-year. For H1 2025, the company achieved total revenue of 870 million yuan, a net loss of 40 million yuan, and a net profit of -40 million yuan, compared to 820 million yuan, -50 million yuan, and -50 million yuan in the same period last year [4]. - Zhongfu Shenying (688295.SH) demonstrated significant improvement in profitability, achieving a turnaround after a year. For H1 2025, the company reported revenue of 920 million yuan, a net profit of 12 million yuan, and a net profit excluding non-recurring items of 2 million yuan, reflecting a year-on-year change of +26%, -52%, and +110% respectively. In Q2 2025, revenue reached 520 million yuan, with a net profit of 60 million yuan and a net profit excluding non-recurring items also at 60 million yuan, showing year-on-year increases of +83%, +440%, and +228% respectively [5]. - Mengke Pharmaceutical (688373.SH) announced a capital increase plan, proposing to issue 164 million shares at a price of 6.3 yuan per share to Nanjing Haiqing Pharmaceutical, raising no more than 1.033 billion yuan. Following the issuance, Haiqing Pharmaceutical will hold a 20% stake in Mengke Pharmaceutical, becoming the controlling shareholder, with individual Zhang Xiantao becoming the actual controller of the company [6].

消息面上，9月22日晚间，盟科药业发布公告称，海鲸药业与公司签署了《附生效条件的向特定对象发 行股份认购协议》，海鲸药业拟认购盟科药业向其发行的1.64亿股普通股，发行完成后，海鲸药业将持 有公司20%股份。同时，盟科药业与海鲸药业双方签订战略合作协议，在相关合作领域深入展开战略合 作，进一步增强双方的核心竞争力和内在价值。 公告显示，盟科药业本次向特定对象发行股票的募集资金总额不超过10.33亿元（含本数），全部用于 公司日常研发与经营投入。 盟科药业（688373）将迎来实控人。盟科药业最新公告显示，南京海鲸药业股份有限公司（以下简 称"海鲸药业"）拟以不超10.33亿元认购盟科药业向其发行的1.64亿股普通股，发行完成后，海鲸药业将 持有公司20%股份，成为公司控股股东，公司实际控制人也将变更为自然人张现涛。 作为一家还未实现盈利的创新药企，截至上半年末，盟科药业货币资金为2.69亿元，经营活动产生的现 金流量净额多年为负，且资产负债率不断攀升。此次定增募资金额将全部用于公司日常研发与经营投 入，极大增加公司现金流。受这一消息影响，盟科药业9月23日斩获"20cm"涨停。 不过这一决定在董事会审议时遭遇 ...

盟科药业表示，公司自有团队覆盖终端医院的广度与深度仍较为有限，产品难以短期内实现进一步爆发 式的增长，需要通过外部赋能进一步提高商业化效率。"公司计划通过本次融资实现产业整合，引入具 有较强销售能力的产业投资人作为公司控股股东，提高公司销售规模与商业化效率，尽早实现产品商业 化利润。"前述负责人称，在医院端，海鲸药业现有产品覆盖的科室与盟科药业的产品拟覆盖的科室重 合度较高。 盟科药业在披露定增预案的同时，还与海鲸药业签订了战略合作协议，双方宣布将在产品商业化合作、 生产协同、产品研发创新互动、资本合作等领域开展战略合作。 盟科药业的此次定增价格为6.30元/股，不低于定价基准日前二十个交易日甲方股票交易均价的80%；定 增后，海鲸药业在自发行结束之日起36个月内不得转让股份。一位不愿具名的行业分析人士认为，目前 盟科药业的股价处于相对高位，该定增价格系盟科药业高位股价的八折且减持受限，是一份较为乐观的 定增方案。受消息影响，截至9月23日收盘，盟科药业涨停报收9.71元/股。 康替唑胺片放量较快，盟科药业的产品拓展也井然有序。在这一背景下，盟科药业为何要以20%的股权 引入新投资方呢？"战略投资者的进入并不 ...

注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） 资金流向方面，该股今日全天主力资金净流入1.14亿元。（数据宝） 盟科药业9月23日龙虎榜 | 买入营业部名称 | 买入金额(万元) | | --- | --- | | 广发证券股份有限公司深圳广电金融中心证券营业部 | 4911.90 | | 瑞银证券有限责任公司上海花园石桥路证券营业部 | 3915.55 | | 中信证券股份有限公司上海分公司 | 3500.99 | | 机构专用 | 3462.02 | | 国泰海通证券股份有限公司总部 | 2957.56 | | 卖出营业部名称 | 卖出金额(万元) | | 国泰海通证券股份有限公司临海巾山中路证券营业部 | 4618.17 | | 中国中金财富证券有限公司上海徐汇区淮海中路证券营业部 | 3734.41 | | 华福证券有限责任公司乐清清远路证券营业部 | 2977.10 | | 国泰海通证券股份有限公司大庆昆仑大街证券营业部 | 2908.89 | | 国泰海通证券股份有限公司总部 | 1750.83 | 9月23日盟科药业（688373）收盘价9.71元，收盘 ...

Core Viewpoint - The announcement from Amgen Pharmaceuticals indicates that Nanjing Haiqing Pharmaceutical Co., Ltd. plans to subscribe for up to 1.033 billion yuan worth of 164 million ordinary shares, which will make Haiqing the controlling shareholder with a 20% stake, changing the actual controller to individual Zhang Xiantao [1][5]. Group 1: Financial Impact - The total amount raised from the private placement will be used entirely for daily research and operational investments, significantly enhancing the company's cash flow [5][9]. - As of mid-2023, Amgen Pharmaceuticals had cash reserves of 269 million yuan, with negative cash flow from operating activities for several years, and a rising debt-to-asset ratio [1][8]. - The company reported projected revenues of approximately 48 million yuan, 91 million yuan, and 130 million yuan for 2022, 2023, and 2024, respectively, with net losses of 220 million yuan, 421 million yuan, and 441 million yuan during the same period [8]. Group 2: Market Reaction - Following the announcement of the private placement and change in control, Amgen Pharmaceuticals' stock hit the daily limit up on September 23, with a closing price of 9.71 yuan per share, reflecting a 20.02% increase [4][5]. - The trading volume reached 1.01 billion yuan, with a turnover rate of 20.43%, and the total market capitalization reached 6.366 billion yuan [4]. Group 3: Governance Changes - After the completion of the private placement, the board of directors will expand from 7 to 9 members, with Haiqing Pharmaceutical entitled to nominate 5 directors, including a chairman candidate [5][9]. - The introduction of a controlling shareholder is expected to improve the governance structure and provide a more stable leadership and decision-making mechanism for the company's long-term development [9][10]. Group 4: Strategic Considerations - Haiqing Pharmaceutical, established in 1991, focuses on formulation business and has a strong financial capability, which is expected to enhance Amgen's production and research capabilities [5][7]. - Amgen Pharmaceuticals has not yet achieved profitability and relies heavily on external manufacturing, with all products currently outsourced to Huahai Pharmaceutical [6][8]. - The company aims to leverage the new investment to accelerate the commercialization of its products and improve its market position in the field of antibiotic resistance [9][10].